SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hill Emily Luisa

(Last)

(First)

(Middle)

C/O PTC THERAPEUTICS INC.

100 CORPORATE COURT

(Street)

SOUTH PLAINFIELD

07080

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/31/2019

3. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,605⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right To Buy)	⁽²⁾	09/24/2024	Common Stock	7,000	$43.69	D
Stock Option (Right To Buy)	⁽²⁾	01/02/2025	Common Stock	1,620	$51	D
Stock Option (Right To Buy)	⁽³⁾	01/03/2026	Common Stock	2,430	$30.86	D
Stock Option (Right To Buy)	⁽⁴⁾	01/02/2027	Common Stock	3,825	$11.23	D
Stock Option (Right To Buy)	⁽⁵⁾	01/03/2028	Common Stock	14,000	$18.01	D
Stock Option (Right To Buy)	⁽⁶⁾	01/21/2029	Common Stock	21,210	$33.02	D

Explanation of Responses:

1. Includes: 1) 179 unvested Restricted Stock Units ("RSUs") from an award of 715 RSUs granted on January 4, 2016, which vests in four equal annual installments over four years, commencing on January 4, 2017; 2) 765 unvested RSUs from an award of 1,530 RSUs granted on January 3, 2017, which vests in four equal annual installments over four years, commencing on January 3, 2018; 3) 1,800 unvested RSUs from an award of 2,400 RSUs granted on January 3, 2018, which vests in four equal annual installments over four years, commencing on January 3, 2019; and 4) 3,636 RSUs granted on January 22, 2019, which vest in four equal annual installments over four years, commencing on January 22, 2020.

2. Currently exercisable.

3. This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.

4. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

5. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

6. This option was granted on January 22, 2019, and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 22, 2020.

Remarks:

	Avraham S. Adler, attorney-in-fact	06/03/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.